Related references
Note: Only part of the references are listed.Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-Fluorouracil in Patients with Advanced Colorectal Cancer
Eric Chen et al.
CLINICAL CANCER RESEARCH (2009)
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group
Glenwood Goss et al.
EUROPEAN JOURNAL OF CANCER (2009)
Molecular control of lymphatic metastasis
Marc G. Achen et al.
LYMPHATIC CONTINUUM REVISITED (2008)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the national cancer institute of Canada clinical trials group
Scott A. Laurie et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Unlocking the biological clues of lung cancer
Nasser Hanna
JOURNAL OF THORACIC ONCOLOGY (2008)
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)
Charles J. Ryan et al.
INVESTIGATIONAL NEW DRUGS (2007)
Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts
Neil R. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2007)
The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model
Fernando Gomez-Rivera et al.
CLINICAL CANCER RESEARCH (2007)
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors
Joachim Drevs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors
CJ Langer et al.
SEMINARS IN ONCOLOGY (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
FA Shepherd et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
